Dr. Paul Ludmer presents a significant intelligence gap for plaintiff attorneys, as his credentials, specialty area, and institutional affiliation remain unverified through standard academic and professional channels. Based on available case data, his expertise appears focused on pharmaceutical litigation, specifically appearing as a plaintiff expert in the Villarreal v. Taro Pharmaceuticals matter in the Southern District of Texas in 2017. The repetitive case entries suggest either multiple plaintiffs in consolidated proceedings or administrative duplications, but the lack of specialty identification raises immediate concerns about his qualifications and the scope of his expert opinions in pharmaceutical product liability cases. From a strategic standpoint, Dr. Ludmer's 100% plaintiff-side track record in pharmaceutical litigation indicates consistent availability for plaintiff work, but the absence of any Daubert challenges—either successful or unsuccessful—suggests limited high-stakes exposure or potentially minimal substantive expert opinion work. This creates both opportunity and risk for plaintiff counsel: while he may be cooperative and aligned with plaintiff theories, the lack of credential verification and absence of tested opinions in federal court present significant Daubert vulnerabilities. His Texas location could provide logistical advantages for regional pharmaceutical cases, but opposing counsel will likely exploit the credentials gap and limited federal court exposure. Plaintiff attorneys should demand comprehensive CV verification and consider this expert only for lower-stakes matters or as supplemental support rather than primary causation testimony, given the high probability of successful Daubert challenges based on qualification deficiencies alone.
No Daubert challenges on record.
Free during beta. Your inquiry will be sent to MTAA and the expert if they've claimed their profile.
We'll send a verification link to your email. Once verified you can add contact info, bio, and availability.